Table S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 1: Selected Adverse Events reported in ≥5 subjects (any grade) or ≥3 subjects for Grade 3 from patients in SR-1. Select immune-related adverse events are also shown.
